The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
 
Ignacio Duran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seattle Genetics
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Roche/Genentech
 
Pablo Maroto
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Janssen
 
Cristina Suárez
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Roche
Speakers' Bureau - Bristol-Myers Squibb; Ipsen
Travel, Accommodations, Expenses - Pfizer; Roche
 
Daniel E. Castellano
Honoraria - Exelixis; MSD; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; MSD; Pfizer; Roche
Speakers' Bureau - Ipsen; Janssen; MSD; Roche
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Roche (Inst)
 
Xavier Garcia del Muro
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; Pfizer; PharmaMar; Roche
Speakers' Bureau - Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer
 
Luis Costa
Consulting or Advisory Role - Exelixis; Novartis; Roche
 
Lidia Martin-Couce
Employment - Ipsen
Stock and Other Ownership Interests - Biogen; Ipsen
 
Fawzi Benzaghou
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Stephane Thomas
Employment - Ipsen; Sanofi Pasteur
Stock and Other Ownership Interests - Ipsen
 
David W. Markby
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Toni K. Choueiri
Honoraria - Alexion Pharmaceuticals; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Journal; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Healthcare; NCCN; NEJM; Novartis; Peloton Therapeutics; PER; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Journal; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Healthcare; NCCN; NEJM; Novartis; Paltform Q; Peloton Therapeutics; Peloton Therapeutics; Pfizer; Prometheus Laboratories; Roche/Genentech; Sanofi/Aventis; UpToDate
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)